Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three agents: - **D-aspartate** is an endogenous amino acid, sometimes used as a dietary supplement, with roles in neurotransmission and hormone regulation. It is not an approved pharmaceutical drug. - **Interferon beta-1a** is a recombinant human protein belonging to the interferon class, used as an immunomodulator primarily for the treatment of relapsing forms of multiple sclerosis. It works by binding to specific cell surface receptors and modulating immune responses, reducing inflammation and preventing nerve damage[1][3][4]. - **Methylprednisolone** is a synthetic glucocorticoid corticosteroid that acts as an anti-inflammatory and immunosuppressant. It modifies the body's immune response and reduces inflammation in various conditions including autoimmune diseases like multiple sclerosis[6][10]. There are no known approved pharmaceutical products or brand names for this exact combination; it appears to be either experimental or theoretical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on D-aspartate + interferon beta-1a + methylprednisolone.